In This Section

Program

Please note that this meeting will take place as an in-person event in Boston and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

[R] – Remote Presentation

TuesDAY, January 20

Wednesday, January 21

Thursday, January 22

Tuesday, January 20

REGISTRATION

3-5 p.m.

Welcome and Introduction

  • Elena Castro, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Peter S. Nelson, Fred Hutchison Cancer Center, Seattle, Washington
  • Patrick G. Pilié, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts

Opening Keynote Address

5:10-5:45 p.m.

  • Francis S. Collins, Former Director of the National Institute of Health (NIH), Bethesda, Maryland

Panel Session/Debate

5:45-6:45 p.m.

Lightning Talks I

6:45-7:15 p.m.

Opening Reception and Poster Session A

7:15-8:45 p.m.

Wednesday, January 21

Continental Breakfast

7-8 a.m.

Plenary Session 1: AI in Prostate Cancer Research

8-8:55 a.m.

  • Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, Massachusetts
  • AI in prostate cancer research
    Stephanie A. Harmon, National Institute of Health, Bethesda, Maryland
  • William R. Sellers, Broad Institute, Cambridge, Massachusetts
  • A digital twin platform to inform and accelerate prostate cancer trials
    Ravi B. Parikh, Emory University, Atlanta, Georgia


Short talk selected from proffered abstracts

Break

9:55-10:15 a.m.

Plenary Session 2: Recent Advances in Risk, Detection, and Diagnosis

10:15 a.m.-12:20 p.m.

  • Advances in using germline genetics to inform prostate cancer risk assessment and disease progression
    Burcu F. Darst, Fred Hutchison Cancer Center, Seattle, Washington
  • A framework for early interception of prostate cancer lineage plasticity
    Sylvan C. Baca, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Recent advances in risk, detection, and diagnosis
    Raquel Perez-Lopez, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Additional speaker to be announced

Lunch on own

12:20-1:45 p.m.

Plenary Session 3: Exploiting the Tumor Microenvironment and Immune Response

1:45-3:25 p.m.

  • Deconvoluting cellular interactions in prostate cancer metastatic niches that promote therapy resistance
    Joshua M. Lang, University of Wisconsin-Madison, Madison, Wisconsin
  • Myeloid-mediated mechanisms of immunosuppression within the prostate cancer tumor microenvironment
    Lawrence Fong, Fred Hutchison Cancer Center, Seattle, Washington
  • Harnessing the TGFβ-LRRC15 axis: A targeted radio-immunotheranostic strategy to predict cancer progression, deplete tumor-promoting mechanisms, and overcome immunotherapy resistance in aggressive malignancies
    David Ulmert, University of California Los Angeles, Los Angeles, California
  • Gustavo E. Ayala, Baylor College of Medicine, Houston, Texas

Additional speaker to be announced

Proffered Talks

3:25-4:25 p.m.

Plenary Session 4: Androgen Receptor: New insights

4:45-6:30 p.m.

  • Understanding the mechanisms by which cells recognize and respond to different levels of androgens has informed new therapeutic approaches for prostate cancer
    Donald P. McDonnell, Duke University, Durham, North Carolina
  • Androgen receptor as a tumor suppressor in castration-resistant prostate cancer
    Laura Sena, Johns Hopkins University, Baltimore, Maryland
  • Elizabeth V. Wasmuth, University of Texas Health at San Antonio, San Antonio, Texas
  • Patrick G. Pilie, MD Anderson Cancer Center, Houston, Texas

Lightning Talks II

6:30 p.m.-7 p.m.

Reception and Poster Session B

7-8:30 p.m.

Thursday, January 22

Continental Breakfast

7-8 a.m.

Plenary Session 5: Genomics and Epigenomics

8-9:25 a.m.

  • Massimo Loda, Weil Cornell Medicine, New York, New York
  • Franklin W. Huang, University of California San Francisco, San Francisco, California
  • Actionable targets in epigenetically distinct subtypes of prostate cancer
    Michael C. Haffner, Fred Hutchison Cancer Center, Seattle, Washington


Short talks selected from proffered abstract

BReak

9:25-9:45 a.m.

Plenary Session 6: Targeting the mechanisms of treatment resistance

9:45-11:10 a.m.

  • Overcoming treatment resistance in aggressive variant prostate cancers, one combination at a time
    Ana Aparicio, MD Anderson Cancer Center, Houston, Texas
  • Martin E. Gleave, University of British Columbia, Vancouver, BC, Canada
  • Justin Hwang, University of Minnesota, Minneapolis, Minnesota


Short talks selected from proffered abstracts

Break

11:10-11:30 a.m.

Keynote 2

11:30 a.m.-12:05 p.m.

  • Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, New York

Plenary Session 7: New models, targets and therapeutics

12:05-1:30 p.m.

  • Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity
    Abhijit Parolia, University of Michigan, Ann Arbor, Michigan
  • Elena Castro, Hospital Universitario 12 de Octubre, Madrid, Spain
  • Targeting MYC with small molecules
    Sarki A. Abdulkadir, Northwestern University, Chicago, Illinois


Short talks selected from proffered abstracts

Closing Remarks and Departure

1:30 p.m.